Experimental: Active "I-Reconstruction" Therapy — Competitive Intelligence Brief

Experimental: Active "I-Reconstruction" Therapy (Experimental: Active "I-Reconstruction" Therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone. Area: Infectious Disease.

marketed Fluoroquinolone DNA gyrase and topoisomerase IV Infectious Disease Small molecule

Target snapshot

Experimental: Active "I-Reconstruction" Therapy (Experimental: Active "I-Reconstruction" Therapy) — International Association Psychosomatics And Health Therapy. Ofloxacin ophthalmic solution is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Experimental: Active "I-Reconstruction" Therapy TARGET	Experimental: Active "I-Reconstruction" Therapy	International Association Psychosomatics And Health Therapy	marketed	Fluoroquinolone	DNA gyrase and topoisomerase IV
Moxifloxacin 0.5% ophthalmic solution	Moxifloxacin 0.5% ophthalmic solution	Johns Hopkins University	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Moxifloxacin HCl 0.5%	Moxifloxacin HCl 0.5%	Carolina Eyecare Physicians, LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
β-lactams or ciprofloxacin	β-lactams or ciprofloxacin	University of Athens	marketed	Antibiotic (β-lactam and fluoroquinolone)	Penicillin-binding proteins (β-lactams); DNA gyrase and topoisomerase IV (ciprofloxacin)
Vigamox Eye Drops	Vigamox Eye Drops	Merck Sharp & Dohme LLC	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
moxifloxacin 0.5% eye drops	moxifloxacin 0.5% eye drops	Allergan	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV
Third generation fluoroquinolone	Third generation fluoroquinolone	University of Roma La Sapienza	marketed	Fluoroquinolone antibiotic	Bacterial DNA gyrase and topoisomerase IV

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone class)

1. Alk Abello · 1 drug in this class
2. Innovative Medical · 1 drug in this class
3. International Association Psychosomatics And Health Therapy · 1 drug in this class
4. National University of Malaysia · 1 drug in this class